Endo International plc - Ordinary Shares (ENDP): Price and Financial Metrics


Endo International plc - Ordinary Shares (ENDP)

Today's Latest Price: $5.39 USD

0.09 (1.70%)

Updated Nov 27 1:00pm

Add ENDP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ENDP Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ENDP is -3.72 -- better than only 3.09% of US stocks.
  • ENDP's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 1.63% of US stocks.
  • Over the past twelve months, ENDP has reported earnings growth of 220.05%, putting it ahead of 93.55% of US stocks in our set.
  • Stocks that are quantitatively similar to ENDP, based on their financial statements, market capitalization, and price volatility, are NCMI, TLGT, ARA, SGMS, and NEWT.
  • ENDP's SEC filings can be seen here. And to visit Endo International plc's official web site, go to www.endo.com.

ENDP Stock Price Chart Interactive Chart >

Price chart for ENDP

ENDP Price/Volume Stats

Current price $5.39 52-week high $7.10
Prev. close $5.30 52-week low $2.08
Day low $5.23 Volume 1,771,200
Day high $5.51 Avg. volume 5,628,601
50-day MA $4.60 Dividend yield N/A
200-day MA $3.96 Market Cap 1.24B

Endo International plc - Ordinary Shares (ENDP) Company Bio


Endo International plc focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The company was founded in 1920 and is based in Dublin, Ireland.

ENDP Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$5.39$1.58 -70%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Endo International plc. To summarize, we found that Endo International plc ranked in the 22th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Endo International plc, consider:

  • Its compound free cash flow growth rate, as measured over the past 5.69 years, is -0.04% -- higher than only 19.42% of stocks in our DCF forecasting set.
  • 13% of the company's capital comes from equity, which is greater than merely 3.87% of stocks in our cash flow based forecasting set.
  • As a business, Endo International plc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than merely 0% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-70%
1%-70%
2%-70%
3%-69%
4%-69%
5%-69%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ENDP, try ABT, CPIX, DHR, EHC, and RHE.


ENDP Latest News Stream


Event/Time News Detail
Loading, please wait...

ENDP Latest Social Stream


Loading social stream, please wait...

View Full ENDP Social Stream

Latest ENDP News From Around the Web

Below are the latest news stories about Endo International plc that investors may wish to consider to help them evaluate ENDP as an investment opportunity.

Endo International plc Announces The Expiration And Final Tender Results Of Its Previously Announced Tender Offer

DUBLIN, Aug. 21, 2020 /PRNewswire/ -- Endo International plc (the "Company") (NASDAQ: ENDP) announced today the expiration and final tender results of the previously announced cash tender offer (the "Offer") by its wholly owned subsidiary Endo Finance LLC ("Endo Finance") for any and all…

PR Newswire | August 21, 2020

TUESDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Endo International plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, CA - (NewMediaWire) - August 12, 2020 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Endo International plc (“Endo” or “the Company”) (NASDAQ: ENDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 8, 2017 and June 10, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before August 18, 2020. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-...

NewMediaWire | August 12, 2020

ENDP DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Endo International plc and Lead Plaintiff Deadline: August 18, 2020

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Endo International plc ("Endo" or the "Company") (NASDAQ: ENDP) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Endo securities between August 8, 2017, and June 10, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/endp. This clas

Business Wire | August 11, 2020

Endo International plc's (ENDP) CEO Blaise Coleman on Q2 2020 Results - Earnings Call Transcript

Endo International plc (ENDP) Q2 2020 Earnings Conference Call August 06, 2020 7:00 AM ET Company Participants Laure Park – Senior Vice President of Investor Relations and Corporate Affairs Blaise Coleman – President and Chief Executive Officer Mark Bradley – Executive Vice President and Chief Financial Officer Patrick Barry –...

SA Transcripts on Seeking Alpha | August 7, 2020

DOJ wants as much as $18.1B From Purdue Pharma for opioid epidemic

The U.S. Department of Justice is demanding OxyContin maker Purdue Pharma pay as much as $18.1B in penalties as part of its bankruptcy reorganization plan, WSJ reports.On the civil side, the DOJ is seeking $2.8B - which could be tripled under the law - for tax dollars spent battling the...

Seeking Alpha | August 5, 2020

Read More 'ENDP' Stories Here

ENDP Price Returns

1-mo 17.94%
3-mo 79.07%
6-mo 49.31%
1-year 6.10%
3-year -26.57%
5-year -91.30%
YTD 14.93%
2019 -35.75%
2018 -5.81%
2017 -52.94%
2016 -73.10%
2015 -15.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9224 seconds.